HotAvitag
Biotinylated Canine FcRn / FCGRT&B2M Heterodimer Protein, His,Avitag™&Tag Free (MALS & SPR verified)Cat. No. FCM-C82W9
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| IMVT-1402 | IMVT-1402; HL-161 ANS | Phase 3 Clinical | HanAll Biopharma Co Ltd | Arthritis, Rheumatoid; Autoimmune Diseases; Graves Disease; Lupus Erythematosus, Cutaneous; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Sjogren's Syndrome | Details |
| STSA-1301 | STSA-1301; STSA1301 | Phase 2 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | Details |
| ARGX-124 | ARGX124; ARGX-124 | Phase 1 Clinical | Argenx Se | Immune System Diseases | Details |
| ARGX-213 | ARGX-213 | Phase 1 Clinical | Argenx Se | Autoimmune Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Efgartigimod alfa | EFG PH20 SC; PH20 SC; ARGX-113-2308; ARGX-113; EFG PH20 | Approved | Argenx Se | VYVDURA, VYVGART HYTRULO, 卫伟迦, VYVGART | United States | Myasthenia Gravis | Argenx BV | 2021-12-17 | Epidermolysis Bullosa; Epidermolysis Bullosa Acquisita; Epidermolysis Bullosa Dystrophica; Eye Diseases; Glomerulonephritis, Membranous; Graves Ophthalmopathy; Guillain-Barre Syndrome; Immunoglobulin G4-Related Disease; Lupus Nephritis; Muscular Diseases; Myasthenia Gravis; Myositis; Nephrosis; Nephrotic Syndrome; Optic Neuritis; Pemphigoid, Bullous; Pemphigus; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Postural Orthostatic Tachycardia Syndrome; Purpura, Thrombocytopenic; Purpura, Thrombocytopenic, Idiopathic; Rejection of organ transplantation; Scleroderma, Systemic; Sjogren's Syndrome; Stiff-Person Syndrome; Tachycardia; Thrombocytopenia | Details |
| Nipocalimab | M-281; JNJ-80202135 | Approved | Momenta Pharmaceuticals Inc | IMAAVY | United States | Myasthenia Gravis | Janssen Biotech Inc | 2025-04-29 | Anemia, Hemolytic, Autoimmune; Arthritis, Rheumatoid; Hemolysis; Lupus Erythematosus, Systemic; Lupus Nephritis; Myasthenia Gravis; Myositis; Pemphigoid, Bullous; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Sjogren's Syndrome; Thrombocytopenia, Neonatal Alloimmune | Details |
| Rozanolixizumab | UCB-7665 | Approved | Ucb Sa | RYSTIGGO, 优迪革 | United States | Myasthenia Gravis | Ucb Inc | 2023-06-27 | Encephalitis; Fibromyalgia; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic | Details |
| Efgartigimod alfa/Hyaluronidase | Approved | Argenx BV | VYVDURA, VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2023-06-20 | Anti-synthetase Syndrome; Dermatomyositis; Muscular Diseases; Myasthenia Gravis; Myositis; Polymyositis; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Details |







